Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Nathanael Gray, Ph.D.

Co-Author

This page shows the publications co-authored by Nathanael Gray and Constantine Mitsiades.
Connection Strength

1.227
  1. An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. Cancer Cell. 2021 02 08; 39(2):240-256.e11.
    View in: PubMed
    Score: 0.235
  2. Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. Cell Rep. 2021 01 05; 34(1):108532.
    View in: PubMed
    Score: 0.235
  3. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014 Jul 31; 511(7511):616-20.
    View in: PubMed
    Score: 0.149
  4. Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol. 2014 May 16; 9(5):1086-91.
    View in: PubMed
    Score: 0.147
  5. Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells. PLoS One. 2013; 8(2):e56473.
    View in: PubMed
    Score: 0.136
  6. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. Leukemia. 2012 Oct; 26(10):2233-44.
    View in: PubMed
    Score: 0.128
  7. Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation. PLoS One. 2011; 6(7):e20226.
    View in: PubMed
    Score: 0.122
  8. Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. Clin Cancer Res. 2014 Nov 01; 20(21):5483-95.
    View in: PubMed
    Score: 0.038
  9. Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia. 2015 Jan; 29(1):27-37.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.